Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, Dillhoff M, Schmidt CR, Shirley LA. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors. Annals Of Surgical Oncology 2018, 25: 3613-3620. PMID: 30182331, DOI: 10.1245/s10434-018-6741-x.Peer-Reviewed Original ResearchConceptsRepeat transarterial chemoembolizationMetastatic neuroendocrine tumorsTransarterial chemoembolizationPancreastatin levelsNeuroendocrine tumorsOverall survivalPrognostic impactImproved overall survivalProgressive liver diseaseFirst transarterial chemoembolizationWorse overall survivalUseful prognostic indicatorLong-term survivalPg/mLConclusionsFor patientsPost TACECarcinoid syndromeTACE treatmentLiver metastasesPatient demographicsImproved survivalLiver diseasePoor outcomePrognostic indicatorResultsA totalManagement outcomes of diverticulitis and colitis in patients with active cancer
Horwood C, Wisler J, Byrd S, Woodling K, Schneider E, Rushing A. Management outcomes of diverticulitis and colitis in patients with active cancer. Surgery 2018, 164: 350-353. PMID: 29801733, DOI: 10.1016/j.surg.2018.03.010.Peer-Reviewed Original ResearchConceptsActive cancer diagnosisColonic emergenciesActive cancerNonoperative managementIntensive care unit admissionEmergent general surgeryCare unit admissionPreoperative risk factorsCancer diagnosisNon-operative managementCancer patient populationIntensive care unitNonoperative groupNonoperative patientsUnit admissionPostoperative complicationsCare unitColonic pathologyOperative groupSurgery consultOperative managementPatient populationCancer DatabaseRisk factorsGeneral surgery